Navigation Links
MultiCell Technologies is Granted Stem Cell Patent
Date:5/31/2011

WOONSOCKET, R.I., May 31, 2011 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) is pleased to announce the issuance of U.S. patent 7,935,528 by the United States Patent and Trademark Office (USPTO) relating to the isolation and use of human liver stem cells to treat liver disease.  Under the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of U.S. patent 7,935,528.  

The patent describes methods to isolate and use human liver stem cells to treat degenerative liver diseases, or inherited deficiencies of liver function.  Patients who suffer from severe, irreversible liver disease for which other medical and surgical treatments have failed are often candidates for a liver transplant.  Liver stem cells which differentiate into functional mature hepatocytes could help to reconstitute a diseased liver, and may be an alternative approach to whole organ transplants for certain liver diseases.

"We are pleased the USPTO has agreed that our liver stem cells are indeed novel and may lead to important therapeutic applications," said W. Gerald Newmin, Chairman and Chief Executive Officer.  "Our efforts to better understand liver stem cell biology, and the role these cells play in chronic liver disease and primary hepatocellular carcinoma, is a major focus of the Company," Mr. Newmin stated.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

An
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
2. MultiCell Technologies Launches New Web Site
3. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
4. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
5. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
6. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
7. TriLink BioTechnologies, Inc. Awarded European Patent for CleanAmp™ Primers
8. Vicor Technologies CEO David H. Fater to Present Live, Online at RetailInvestorConferences.com
9. Mind Technologies Inc. Developing Revolutionary EEG Brain Computer Interface
10. Patient Safety Technologies Reports First Quarter 2011 Results
11. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
(Date:11/26/2014)... 26, 2014 Scott Steiger lives in ... world. As an engineer for the past 20 years, he,s traveled ... military service. He,s been to six of the seven continents. Travel ... - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... has a pretty good idea of what,s required. His ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... Calif., Feb. 23, 2012 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with inflammation and autoimmune ... and Chief Executive Officer, will provide a corporate presentation ... York, NY on Monday, February 27, 2012, at approximately ...
... Telik, Inc. (Nasdaq: TELK ) reported a net loss ... ended December 31, 2011, compared with a net loss of $9.8 ...  For the year ended December 31, 2011, net loss was $12.0 ... $24.7 million, or $0.46 per share, for the year ended December ...
Cached Medicine Technology:Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 2Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 3Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 4Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 5Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 6
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter ... brains seem pre-wired to acquire a second language, new research ... tongue will likely gain a brain boost, the small study ... after learning," said study co-author Ping Li, co-director of the ... But it,s even more interesting, Li said, that "the brain ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... November 27, 2014 VogueQueen.com is making ... for ladies across the world. As the premier online ... VogueQueen.com is proud to release a huge selection of ... quality outfits, it is also providing many beautiful styles ... prom gowns at discounted prices. , “VogueQueen.com hopes ...
(Date:11/27/2014)... Dallas, Texas (PRWEB) November 27, 2014 ... research report on Global Insulin industry. For an ... including definition, classification, application, industry chain structure, industry ... report on global Insulin industry covers information ... manufacturing process, product cost structure and much more. ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... laughter as we enjoy the ugly sweater contest." Last ... scratch. " It was a sight to see. She ... enough, the Christmas balls were faces of the staff with ... participating this year, it's simple to get in on the ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
... in German . , On 7 ... in Health Care (IQWiG) published the results of a ... heart disease (CHD). The aim of the report is ... methodological quality that may be relevant for the planned ...
... undergoing radiation treatments for head and neck cancer fare ... according to a study in the February issue of ... official journal of the American Society for Radiation Oncology ... smoking and head and neck cancers has long been ...
... have discovered a novel function of brain insulin, indicating that ... unrestrained lipolysis that initiates and worsens type 2 diabetes in ... Cell Metabolism . Led by Christoph Buettner, MD, ... and Bone Disease at Mount Sinai School of Medicine, the ...
... HealthDay Reporter , TUESDAY, Feb. 15 (HealthDay News) -- ... they,re first tested may not need to be screened annually ... study suggests. Dutch researchers presenting the findings at ... men with a PSA below 3.0 ng/ml were likely to ...
... Feb. 15 (HealthDay News) -- Men with prostate cancer may be ... baldness at the age of 20 than those without prostate cancer, ... hair in their 30s or 40s do not appear to face ... loss starts in their 20s do not face a higher risk ...
... more likely to be readmitted to the hospital after a ... pneumonia, according to a new study from Harvard School of ... rates were due to disparities related to both race and ... health and health care are well-documented in this country, but ...
Cached Medicine News:Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 3Health News:Smoking during radiation treatments reduces chance of overall survival 2Health News:Researchers find brain insulin plays critical role in the development of diabetes 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 3Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 2Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 3Health News:Study finds blacks more likely to be readmitted to hospitals after discharge 2
The Natural Selection family of specialty allografts are spinal allograft devices to eliminate the need for painful autograft harvesting....
... Corlok Allografts are unique corticocancellous allografts ... and a unique Dovetail geometry permitting ... vertebrae. Corlok Allografts are processed from ... allograft implants. Specially designed instruments facilitate ...
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
... Anteater Titanium Microdiscectomy System offers strength ... surgery. The boss anteater titanium microdiscectomy ... intervertebral discs provides for less invasive ... retractor is designed to provide low ...
Medicine Products: